 |
|
Effect of Pioglitazone Compared With Glimepiride on Carotid Intima-Media Thickness in Type 2 Diabetes
A Randomized Trial
Theodore Mazzone, MD;
Peter M. Meyer, PhD;
Steven B. Feinstein, MD;
Michael H. Davidson, MD;
George T. Kondos, MD;
Ralph B. D’Agostino, Sr, PhD;
Alfonso Perez, MD;
Jean-Claude Provost, MD;
Steven M. Haffner, MD
JAMA. 2006;296:2572-2581. Published online November 13, 2006 (doi:10.1001/jama.296.21.joc60158)
Context Carotid artery intima-media thickness (CIMT) is a marker of coronary atherosclerosis and independently predicts cardiovascular events, which are increased in type 2 diabetes mellitus (DM). While studies of relatively short duration have suggested that thiazolidinediones such as pioglitazone might reduce progression of CIMT in persons with diabetes, the results of longer studies have been less clear.
Objective To evaluate the effect of pioglitazone vs glimepiride on changes in CIMT of the common carotid artery in patients with type 2 DM.
Design, Setting, and Participants Randomized, double-blind, comparator-controlled, multicenter trial in patients with type 2 DM conducted at 28 clinical sites in the multiracial/ethnic Chicago metropolitan area between October 2003 and May 2006. The treatment period was 72 weeks (1-week follow-up). CIMT images were captured by a single ultrasonographer at 1 center and read by a single treatment-blinded reader using automated edge-detection technology. Participants were 462 adults (mean age, 60 [SD, 8.1] years; mean body mass index, 32 [SD, 5.1]) with type 2 DM (mean duration, 7.7 [SD, 7.2] years; mean glycosylated hemoglobin [HbA1c] value, 7.4% [SD, 1.0%]), either newly diagnosed or currently treated with diet and exercise, sulfonylurea, metformin, insulin, or a combination thereof.
Interventions Pioglitazone hydrochloride (15-45 mg/d) or glimepiride (1-4 mg/d) as an active comparator.
Main Outcome Measure Absolute change from baseline to final visit in mean posterior-wall CIMT of the left and right common carotid arteries.
Results Mean change in CIMT was less with pioglitazone vs glimepiride at all time points (weeks 24, 48, 72). At week 72, the primary end point of progression of mean CIMT was less with pioglitazone vs glimepiride (–0.001 mm vs +0.012 mm, respectively; difference, –0.013 mm; 95% confidence interval, –0.024 to –0.002; P = .02). Pioglitazone also slowed progression of maximum CIMT compared with glimepiride (0.002 mm vs 0.026 mm, respectively, at 72 weeks; difference, –0.024 mm; 95% confidence interval, –0.042 to –0.006; P = .008). The beneficial effect of pioglitazone on mean CIMT was similar across prespecified subgroups based on age, sex, systolic blood pressure, duration of DM, body mass index, HbA1c value, and statin use.
Conclusion Over an 18-month treatment period in patients with type 2 DM, pioglitazone slowed progression of CIMT compared with glimepiride.
Trial Registration clinicaltrials.gov Identifier: NCT00225264
Author Affiliations: Department of Medicine, Section of Endocrinology, Diabetes and Metabolism (Dr Mazzone) and Section of Cardiology (Dr Kondos), University of Illinois College of Medicine, Chicago; Departments of Preventive Medicine (Dr Meyer) and Medicine, Section of Cardiology (Drs Feinstein and Davidson), Rush University Medical Center, Chicago; Department of Mathematics, Statistics and Consulting Unit, Boston University, Boston, Mass (Dr D’Agostino); Takeda Global Research and Development Inc, Lincolnshire, Ill (Dr Perez); Synarc, Paris, France (Dr Provost); and Department of Medicine, University of Texas Health Science Center at San Antonio (Dr Haffner).
RELATED LETTERS
Pioglitazone vs Glimepiride and Carotid Intima-Media Thickness
Dario Giugliano and Katherine Esposito
JAMA. 2007;297(12):1315-1316.
EXTRACT
| FULL TEXT
Pioglitazone vs Glimepiride and Carotid Intima-Media Thickness
Yujiro Kida and Tetsuji Sato
JAMA. 2007;297(12):1316.
EXTRACT
| FULL TEXT
Pioglitazone vs Glimepiride and Carotid Intima-Media Thickness—Reply
Theodore Mazzone
JAMA. 2007;297(12):1316-1317.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Oral Hypoglycemic Use and the SANDS Trial
Evans et al.
JAMA 2008;300:389-389.
FULL TEXT
Effect of Diabetes on Progression of Coronary Atherosclerosis and Arterial Remodeling: A Pooled Analysis of 5 Intravascular Ultrasound Trials
Nicholls et al.
J Am Coll Cardiol 2008;52:255-262.
ABSTRACT
| FULL TEXT
The Peroxisome Proliferator-Activated Receptor-{gamma} Agonist Pioglitazone Represses Inflammation in a Peroxisome Proliferator-Activated Receptor-{alpha}-Dependent Manner In Vitro and In Vivo in Mice
Orasanu et al.
J Am Coll Cardiol 2008;0:j.jacc.2008.04.055v1-14006.
ABSTRACT
| FULL TEXT
How to interpret figures in reports of clinical trials
Pocock et al.
BMJ 2008;336:1166-1169.
FULL TEXT
Think Beyond the Numbers, Don't Forget the Patient
Repas
JAOA: Journal of the American Osteopathic Association 2008;108:ii-S4.
FULL TEXT
Increased High-Density Lipoprotein Cholesterol Predicts the Pioglitazone-Mediated Reduction of Carotid Intima-Media Thickness Progression in Patients With Type 2 Diabetes Mellitus
Davidson et al.
Circulation 2008;117:2123-2130.
ABSTRACT
| FULL TEXT
Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes: The PERISCOPE Randomized Controlled Trial
Nissen et al.
JAMA 2008;299:1561-1573.
ABSTRACT
| FULL TEXT
Does PERISCOPE Provide a New Perspective on Diabetic Treatment?
Steg and Marre
JAMA 2008;299:1603-1604.
FULL TEXT
Osteoprotegerin, Thiazolidinediones Treatment, and Silent Myocardial Ischemia in Type 2 Diabetic Patients
Sultan et al.
Diabetes Care 2008;31:593-595.
FULL TEXT
Beneficial Effects of Pioglitazone on Hypertensive Cardiovascular Injury Are Enhanced by Combination With Candesartan
Nakamura et al.
Hypertension 2008;51:296-301.
ABSTRACT
| FULL TEXT
New Drugs for the Treatment of Diabetes Mellitus: Part I: Thiazolidinediones and Their Evolving Cardiovascular Implications
McGuire and Inzucchi
Circulation 2008;117:440-449.
FULL TEXT
Thiazolidinediones and Cardiovascular Outcomes in Older Patients With Diabetes
Lipscombe et al.
JAMA 2007;298:2634-2643.
ABSTRACT
| FULL TEXT
Links Between Adipose Tissue and Thrombosis in the Mouse
Bodary
Arterioscler. Thromb. Vasc. Bio. 2007;27:2284-2291.
ABSTRACT
| FULL TEXT
Nateglinide Reduces Carotid Intima-Media Thickening in Type 2 Diabetic Patients Under Good Glycemic Control
Mita et al.
Arterioscler. Thromb. Vasc. Bio. 2007;27:2456-2462.
ABSTRACT
| FULL TEXT
Carotid Intima-Media Thickness in Confirmed Prehypertensive Subjects: Predictors and Progression
Femia et al.
Arterioscler. Thromb. Vasc. Bio. 2007;27:2244-2249.
ABSTRACT
| FULL TEXT
The Peroxisome Proliferator Activated Receptor-{gamma} Agonist Pioglitazone Increases Number and Function of Endothelial Progenitor Cells in Patients With Coronary Artery Disease and Normal Glucose Tolerance
Werner et al.
Diabetes 2007;56:2609-2615.
ABSTRACT
| FULL TEXT
Artery-Related Differences in Atherosclerosis Expression: Implications for Atherogenesis and Dynamics in Intima-Media Thickness
Dalager et al.
Stroke 2007;38:2698-2705.
ABSTRACT
| FULL TEXT
Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Trials
Lincoff et al.
JAMA 2007;298:1180-1188.
ABSTRACT
| FULL TEXT
Long-term Risk of Cardiovascular Events With Rosiglitazone: A Meta-analysis
Singh et al.
JAMA 2007;298:1189-1195.
ABSTRACT
| FULL TEXT
The Avandia Debate
Bloomgarden
Diabetes Care 2007;30:2401-2408.
FULL TEXT
Avandia Study Gets Mixed Reviews
Law
DOC News 2007;4:20-24.
FULL TEXT
Point: Recent Long-Term Clinical Studies Support an Enhanced Role for Thiazolidinediones in the Management of Type 2 Diabetes
Kahn and Zinman
Diabetes Care 2007;30:1672-1676.
FULL TEXT
Combined Low-Dose Pioglitazone, Flutamide, and Metformin for Women with Androgen Excess
Ibanez et al.
J. Clin. Endocrinol. Metab. 2007;92:1710-1714.
ABSTRACT
| FULL TEXT
Fluid Retention With Thiazolidinediones: Does the Mechanism Influence the Outcome?
Lindenfeld and Masoudi
J Am Coll Cardiol 2007;49:1705-1707.
FULL TEXT
Pioglitazone vs Glimepiride and Carotid Intima-Media Thickness
Giugliano and Esposito
JAMA 2007;297:1315-1316.
FULL TEXT
Pioglitazone vs Glimepiride and Carotid Intima-Media Thickness
Kida and Sato
JAMA 2007;297:1316-1316.
FULL TEXT
Kidney disease in diabetology
Schernthaner
Nephrol Dial Transplant 2007;22:703-707.
FULL TEXT
Relationship of Traditional and Nontraditional Cardiovascular Risk Factors to Coronary Artery Calcium in Type 2 Diabetes
Mazzone et al.
Diabetes 2007;56:849-855.
ABSTRACT
| FULL TEXT
Peroxisome Proliferator Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets
Brown and Plutzky
Circulation 2007;115:518-533.
ABSTRACT
| FULL TEXT
TZD Therapy Thought to Slow Atherosclerosis in People With Diabetes
Goldfarb
DOC News 2007;4:1-12.
FULL TEXT
Pioglitazone vs. Glimepiride in Type 2 Diabetes
Journal Watch Cardiology 2006;2006:2-2.
FULL TEXT
|
